Sign Out
Adjuvant treatment of post-menopausal women with hormone receptor positive early invasive breast cancer.
Adjuvant treatment of early breast cancer in hormone receptor positive post-menopausal women who have received 2 to 3 years of adjuvant tamoxifen.
Treatment of advanced breast cancer in post-menopausal women. Efficacy has not been demonstrated in oestrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen.
